/

IVVD

Invivyd, Inc.Open

0.6500−0.02 −3.46%USD

NasdaqGM · as of Oct 13, 14:51 ET · 15m delay

Open

0.6600

Prev close

0.6733

Day range

0.64000.6731

52-week range

0.52803.07

Volume

2.90M0.59×

Mkt cap

191.59M

P/E ttm

—

Fwd P/E

-1.18

EPS ttm

-0.3300

Div yield

0.00%

Earnings

—

From 52w high

−78.83%

Price Chart

Yahoo Finance · delayed

IVVDOct 13, 2026O 0.6600H 0.6731L 0.6400C 0.6500−0.0230 (−3.42%)Vol 2.90M

SMA 500.8187
SMA 2001.2869

1Y change −63.07% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

IVVD Invivyd, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −19.35%
1 month: −17.30%
3 months: −18.85%
6 months: −59.63%
Year to date: −73.68%
1 year: −65.43%

Valuation & ownership

Market cap: 191.59M
Enterprise value: 46.77M
P/E (ttm): —
Forward P/E: -1.18
PEG ratio: —
Price / book: 1.06
Price / sales (ttm): 3.28
EV / EBITDA: -0.42
EPS (ttm): -0.3300
EPS (forward): -0.5500
Beta (5y monthly): 0.95
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 294.76M
Float: 207.83M
Short % of float: 12.69%
Short ratio (days): 4.96
Held by insiders: 7.16%
Held by institutions: 86.94%
Avg volume (3m): 4.92M
50-day average: 0.8168
200-day average: 1.30
52-week change: −65.43%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 35.8
vs 50-day SMA: −20.61%
vs 200-day SMA: −49.49%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 11.72%
Realised vol (20d, ann.): 135.2%
From 52-week high: −78.83%
From 52-week low: +23.11%

ANR

Analyst Consensus

3 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

10.00

+1,438.46% implied

Low 10.00Median 10.00High 10.00

Recommendation trend

Now3 / 0 / 0
1m ago3 / 0 / 0
2m ago

DES

About Invivyd, Inc.

Yahoo Finance profile

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.

Sector: Healthcare
Industry: Biotechnology
Employees: 122
Headquarters: New Haven, CT, United States
Website: invivyd.com
Officers: Mr. Marc William Elia CEO & Chairperson of the Board
Mr. William E. Duke Jr., M.B.A. CFO and Principal Financial & Accounting Officer
Ms. Jill Andersen J.D.

SEAS

Seasonality · IVVD

2021–2026 · monthly returns

Strongest month Feb +43.98%Weakest month Mar −24.44%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-29.6	-2.9	-23.1	7.7	-18.6	-23.5	-38.6	78.5	-8.9	-25.3			−73.7%
2025	-19.2	224.0	-47.8	4.1	48.4	-23.5	-2.9	40.2	13.1	60.0	38.1	1.6	+457.6%
2024	21.1	-17.6	13.0	-50.0	-17.1	-40.2	13.6	-32.0	20.0	-12.5	-21.7	-36.6	−88.8%
2023	52.0	-23.7	-31.0	-8.3	63.6	-41.7	41.0	25.7	-8.6	-7.1	-3.2	157.5	+162.7%
2022	-1.1	-6.8	-31.8	-37.3	3.5	10.8	7.3	29.5	-31.4	26.2	-42.8	-33.6	−79.3%
2021									24.8	-30.8	60.9	-84.6	−78.5%

INSD

Insider Activity · IVVD

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

578K shares

Sells, 6 months

228K shares

Net shares

+350K

Net change in insider shares

+1.70%

Date	Insider	Transaction	Shares	Value
Aug 17, 2026	Duke William E. Jr.Chief Financial Officer	Sale at price 0.72 - 0.84 per share.	40.8K	$31.67K
Aug 17, 2026	Andersen JillOfficer	Sale at price 0.72 - 0.84 per share.	68K	$52.78K
Aug 17, 2026	Allen Robert D IiiOfficer	Sale at price 0.72 - 0.84 per share.	37.7K	$29.30K
Aug 17, 2026	Green JulieOfficer	Sale at price 0.72 - 0.84 per share.	40.8K	$31.67K
Aug 17, 2026	Lee Edward TimothyOfficer	Sale at price 0.72 - 0.84 per share.	40.8K	$31.67K
Aug 13, 2026	Duke William E. Jr.Chief Financial Officer	—	102K	—
Aug 13, 2026	Andersen JillOfficer	—	170K	—
Aug 13, 2026	Allen Robert D IiiOfficer	—	102K	—
Aug 13, 2026	Green JulieOfficer	—	102K	—
Aug 13, 2026	Lee Edward TimothyOfficer	—	102K	—
Feb 17, 2026	Duke William E. Jr.Chief Financial Officer	Sale at price 1.54 - 1.58 per share.	40.6K	$63.35K
Feb 17, 2026	Andersen JillOfficer	Sale at price 1.54 - 1.58 per share.	67.7K	$105.58K
Feb 17, 2026	Allen Robert D IiiOfficer	Sale at price 1.54 - 1.58 per share.	37.6K	$58.60K
Feb 17, 2026	Green JulieOfficer	Sale at price 1.54 - 1.58 per share.	40.6K	$63.35K
Feb 17, 2026	Lee Edward TimothyOfficer	Sale at price 1.54 - 1.58 per share.	40.6K	$63.35K
Feb 12, 2026	Duke William E. Jr.Chief Financial Officer	—	99K	—
Feb 12, 2026	Andersen JillOfficer	—	165K	—
Feb 12, 2026	Allen Robert D IiiOfficer	—	99K	—
Feb 12, 2026	Green JulieOfficer	—	99K	—
Feb 12, 2026	Lee Edward TimothyOfficer	—	99K	—

13F

Investors Holding IVVD

latest 13F filings of 29 followed managers

Investors holding IVVD
Investor	Value	Of portfolio	Shares	Change	Quarter
Maverick Capital · Lee Ainslie	$16.6M	0.15%	18.97M	—	Q2 2026
Renaissance Technologies	$868.3K	0.00%	995.33K	+18%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

IVVD

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

IVVD

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Invivyd, Inc.

Seasonality · IVVD

Insider Activity · IVVD

Congress Trades · IVVD

Investors Holding IVVD

Investors Holding IVVD

Congress Trades · IVVD

Insider Activity · IVVD

Seasonality · IVVD

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Invivyd, Inc.

Financial Snapshot

Earnings & Dividends

News